$80 Million

Spero Therapeutics

Follow-on Offering

Lead Left Bookrunner, September 2020

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on the unmet needs of patients with drug-resistant bacterial infections. Tebipenem pivoxil hydrobromide, or tebipenem HBr (previously SPR994), the Company’s lead product candidate, is a novel antibiotic with potential to be the first broad-spectrum oral carbapenem approved for use in adults. Additionally, the Company is developing SPR720, an oral antibiotic designed for the treatment of mycobacterial infections, such as non-tuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection.

More Like This

Sep 2020
$86 Million

Follow-on Offering

Bookrunner

View Details
Sep 2020
$150 Million

Follow-on Offering

Lead Left Bookrunner

View Details
Sep 2020
$287 Million

Follow-on Offering

Bookrunner

View Details